MedElevator
Войти в исследования Cell · 2024
Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mucker Eric M, Freyn Alec W, Bixler Sandra L, Cizmeci Deniz, Atyeo Caroline, Earl Patricia L, Natarajan Harini, Santos Genesis, Frey Tiffany R, Levin Rafael H, Meni Anusha, Arunkumar Guha A, Stadlbauer Daniel, Jorquera Patricia A, Bennett Hamilton, Johnson Joshua C, Hardcastle Kath, Americo Jeffrey L, Cotter Catherine A, Koehler Jeff W, Davis Christopher I, Shamblin Joshua D, Ostrowski Kristin, Raymond Jo Lynne, Ricks Keersten M, Carfi Andrea, Yu Wen-Han, Sullivan Nancy J, Moss Bernard, Alter Galit, Hooper Jay W
Аннотация
In 2022, mpox virus (MPXV) spread worldwide, causing 99,581 mpox cases in 121 countries. Modified vaccinia Ankara (MVA) vaccine use reduced disease in at-risk populations but failed to deliver complete protection. Lag in manufacturing and distribution of MVA resulted in additional MPXV spread, with 12,000 reported cases in 2023 and an additional outbreak in Central Africa of clade I virus. These outbreaks highlight the threat of zoonotic spillover by Orthopoxviruses. mRNA-1769, an mRNA-lipid nanoparticle (LNP) vaccine expressing MPXV surface proteins, was tested in a lethal MPXV primate model. Similar to MVA, mRNA-1769 conferred protection against challenge and further mitigated symptoms and disease duration. Antibody profiling revealed a collaborative role between neutralizing and Fc-functional extracellular virion (EV)-specific antibodies in viral restriction and ospinophagocytic and cytotoxic antibody functions in protection against lesions. mRNA-1769 enhanced viral control and disease attenuation compared with MVA, highlighting the potential for mRNA vaccines to mitigate future pandemic threats.